Analyst Price Target is $161.67
▼ -9.16% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $161.67, with a high forecast of $181.00 and a low forecast of $124.00. The average price target represents a -9.16% upside from the last price of $177.96.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Medpace. This rating has held steady since September 2020, when it changed from a Hold consensus rating.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.